|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
JP2013517798A
(ja)
*
|
2010-01-28 |
2013-05-20 |
ザ チルドレンズ ホスピタル オブ フィラデルフィア |
ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
|
|
WO2011133890A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
JP6198278B2
(ja)
*
|
2011-09-08 |
2017-09-20 |
ユニキュアー アイピー ビー．ブイ． |
Ａａｖ調製物からの混入ウイルスの除去
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
FR3002237B1
(fr)
*
|
2013-02-15 |
2017-12-15 |
Genethon |
Methodes pour la production de particules virales aav double brin
|
|
ES2690643T3
(es)
|
2013-11-26 |
2018-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vectores virales adeno-asociados para el tratamiento de enfermedad de almacenamiento de glucógeno
|
|
GB201401707D0
(en)
|
2014-01-31 |
2014-03-19 |
Sec Dep For Health The |
Adeno-associated viral vectors
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
US10280418B2
(en)
|
2014-03-18 |
2019-05-07 |
Univeristy Of Massachusetts |
RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
CN115252823A
(zh)
*
|
2014-03-21 |
2022-11-01 |
建新公司 |
用于色素性视网膜炎的基因疗法
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
US11555059B2
(en)
|
2014-04-25 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
LDLR variants and their use in compositions for reducing cholesterol levels
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
US10370432B2
(en)
|
2014-10-03 |
2019-08-06 |
University Of Massachusetts |
Heterologous targeting peptide grafted AAVS
|
|
JP6842410B2
(ja)
|
2014-10-03 |
2021-03-17 |
ユニバーシティ オブ マサチューセッツ |
新規の高効率ライブラリーにより同定されるａａｖベクター
|
|
AU2015335923B2
(en)
|
2014-10-21 |
2021-04-29 |
University Of Massachusetts |
Recombinant AAV variants and uses thereof
|
|
EP3591070B1
(en)
*
|
2014-11-28 |
2022-12-21 |
uniQure IP B.V. |
Dna impurities in a composition comprising a parvoviral virion
|
|
CA2972038C
(en)
|
2014-12-23 |
2023-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adeno-associated virus vectors encoding modified g6pc and uses thereof
|
|
US9862936B2
(en)
|
2015-01-13 |
2018-01-09 |
Alfa Wassermann, Inc. |
Methods of purifying adeno-associated virus (AAV) and/or recombinant adeno-associated virus (rAAV) and gradients and flow-through buffers therefore
|
|
EP3054007A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
|
|
EP3054006A1
(en)
|
2015-02-09 |
2016-08-10 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Recombinant adeno-associated virus particle purification with multiple-step anion exchange chromatography
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
EP3262162A4
(en)
*
|
2015-02-23 |
2018-08-08 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3283126B1
(en)
|
2015-04-16 |
2019-11-06 |
Emory University |
Recombinant promoters and vectors for protein expression in liver and use thereof
|
|
ES2856936T3
(es)
|
2015-04-23 |
2021-09-28 |
Univ Washington State |
Suministro del gen Smad7 como un agente terapéutico
|
|
WO2016172008A1
(en)
|
2015-04-24 |
2016-10-27 |
University Of Massachusetts |
Modified aav constructions and uses thereof
|
|
CA3002980A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
ES2978086T3
(es)
|
2015-10-22 |
2024-09-05 |
Univ Massachusetts |
Terapia génica con aspartoacilasa en el tratamiento de enfermedad de Canavan
|
|
CN105420275A
(zh)
*
|
2015-11-27 |
2016-03-23 |
中国科学院苏州生物医学工程技术研究所 |
制备外源功能基因定点整合的人神经干细胞的方法
|
|
ES2918998T3
(es)
|
2015-12-11 |
2022-07-21 |
Univ Pennsylvania |
Método de purificación escalable para AAVrh10
|
|
WO2017100674A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav1
|
|
US11015174B2
(en)
*
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
|
US11098286B2
(en)
*
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
US10889832B2
(en)
*
|
2015-12-11 |
2021-01-12 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
JP7128741B2
(ja)
|
2015-12-18 |
2022-08-31 |
サンガモ セラピューティクス， インコーポレイテッド |
Ｔ細胞受容体の標的化破壊
|
|
WO2017106537A2
(en)
|
2015-12-18 |
2017-06-22 |
Sangamo Biosciences, Inc. |
Targeted disruption of the mhc cell receptor
|
|
US10724020B2
(en)
|
2016-02-02 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
Compositions for linking DNA-binding domains and cleavage domains
|
|
US11826433B2
(en)
|
2016-02-02 |
2023-11-28 |
University Of Massachusetts |
Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system
|
|
US12070510B2
(en)
|
2016-02-05 |
2024-08-27 |
Emory University |
Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid
|
|
EP4094780A3
(en)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
PE20190434A1
(es)
*
|
2016-03-31 |
2019-03-21 |
Spark Therapeutics Inc |
PROCESO DE PRODUCCION DE rAAV A BASE DE COLUMNAS COMPLETAMENTE ESCALABLE
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
US11413356B2
(en)
|
2016-04-15 |
2022-08-16 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
GB201612248D0
(en)
|
2016-07-14 |
2016-08-31 |
Puridify Ltd |
New process
|
|
SG11201900366QA
(en)
*
|
2016-07-21 |
2019-02-27 |
Spark Therapeutics Inc |
Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
EP3510161A4
(en)
|
2016-08-23 |
2020-04-22 |
Akouos, Inc. |
COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING DEFICIENCY IN A HUMAN SUBJECT
|
|
ES2901989T3
(es)
|
2016-08-24 |
2022-03-24 |
Sangamo Therapeutics Inc |
Nucleasas específicas de objetivo modificadas
|
|
MX2019002207A
(es)
|
2016-08-24 |
2019-07-15 |
Sangamo Therapeutics Inc |
Regulacion de la expresion genica usando nucleasas modificadas.
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
|
US11000561B2
(en)
|
2016-11-04 |
2021-05-11 |
Takeda Pharmaceutical Company Limited |
Adeno-associated virus purification methods
|
|
EP3321357A1
(en)
|
2016-11-09 |
2018-05-16 |
Deutsches Krebsforschungszentrum |
Scalable process for oncolytic rat parvovirus h-1 production and purification based on isoelectric point-based elimination of empty particles
|
|
JP2020506695A
(ja)
|
2017-01-30 |
2020-03-05 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
糖原病を処置するための組換えウイルスベクター
|
|
CN110612119B
(zh)
|
2017-02-07 |
2024-10-29 |
西雅图儿童医院（Dba西雅图儿童研究所） |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
|
AU2018220212A1
(en)
|
2017-02-20 |
2019-08-08 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
JP7327803B2
(ja)
|
2017-05-09 |
2023-08-16 |
ユニバーシティ オブ マサチューセッツ |
筋萎縮性側索硬化症（ａｌｓ）を処置する方法
|
|
US11633504B2
(en)
|
2017-05-09 |
2023-04-25 |
Emory University |
Nucleic acids encoding clotting factor variants and their use
|
|
MY207281A
(en)
|
2017-06-07 |
2025-02-13 |
Spark Therapeutics Inc |
Enhancing agents for improved cell transfection and/or raav vector production
|
|
AU2018291023B2
(en)
*
|
2017-06-30 |
2023-11-02 |
Spark Therapeutics, Inc. |
AAV vector column purification methods
|
|
BR112020002438A2
(pt)
|
2017-08-08 |
2020-07-28 |
Sangamo Therapeutics, Inc. |
direcionamento celular mediado por receptores de antígenos quiméricos
|
|
AU2018338188B2
(en)
|
2017-09-22 |
2025-02-20 |
University Of Massachusetts |
SOD1 dual expression vectors and uses thereof
|
|
BR112020007790A2
(pt)
|
2017-10-20 |
2020-10-20 |
Research Institute At Nationwide Children's Hospital |
métodos e materiais para terapia genética com nt-3
|
|
IL274430B2
(en)
*
|
2017-11-08 |
2025-01-01 |
Novartis Gene Therapies Inc |
Means and method for preparing viral vectors and their uses
|
|
CN120154716A
(zh)
|
2018-01-22 |
2025-06-17 |
恩多塞特公司 |
Car t细胞的使用方法
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
BR112020015798A2
(pt)
|
2018-02-01 |
2021-03-09 |
Homology Medicines, Inc. |
Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
|
|
CN111936518A
(zh)
|
2018-02-06 |
2020-11-13 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
EP3758736B1
(en)
|
2018-03-02 |
2024-05-01 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Il-34 for use in a method of treating retinal inflammation and neurodegeneration
|
|
SG11202009698PA
(en)
*
|
2018-04-05 |
2020-10-29 |
Nightstarx Ltd |
Aav compositions, methods of making and methods of use
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
JP7478675B2
(ja)
|
2018-06-08 |
2024-05-07 |
ノバルティス アーゲー |
薬物製品の効力を測定するための細胞ベースアッセイ
|
|
JP2021529001A
(ja)
|
2018-06-29 |
2021-10-28 |
ウーハン ニューロフス バイオテクノロジー リミテッド カンパニーＷｕｈａｎ Ｎｅｕｒｏｐｈｔｈ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ |
レーベル遺伝性視神経症を治療するための組成物及び方法
|
|
CN112584874A
(zh)
|
2018-08-20 |
2021-03-30 |
武汉纽福斯生物科技有限公司 |
用于治疗莱伯氏遗传性视神经病变的组合物和方法
|
|
WO2020061426A2
(en)
|
2018-09-21 |
2020-03-26 |
Acuitas Therapeutics, Inc. |
Systems and methods for manufacturing lipid nanoparticles and liposomes
|
|
US20220001028A1
(en)
*
|
2018-11-30 |
2022-01-06 |
Novartis Ag |
Aav viral vectors and uses thereof
|
|
US20220017922A1
(en)
|
2018-12-18 |
2022-01-20 |
Ultragenyx Pharmaceutical Inc. |
Methods and compositions for treating glycogen storage diseases
|
|
PT3906066T
(pt)
|
2019-01-04 |
2024-02-06 |
Ultragenyx Pharmaceutical Inc |
Constructos de terapia génica para o tratamento da doença de wilson
|
|
DK3908568T3
(da)
|
2019-01-11 |
2024-08-26 |
Acuitas Therapeutics Inc |
Lipider til lipidnanopartikellevering af aktivstoffer
|
|
WO2020150556A1
(en)
*
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
US12173290B2
(en)
|
2019-06-28 |
2024-12-24 |
Crispr Therapeutics Ag |
Materials and methods for controlling gene editing
|
|
KR20220035937A
(ko)
|
2019-07-25 |
2022-03-22 |
노파르티스 아게 |
조절 가능한 발현 시스템
|
|
WO2021062012A1
(en)
|
2019-09-25 |
2021-04-01 |
Emory University |
Use of klk10 and engineered derivatizations thereof
|
|
CN113025633B
(zh)
|
2019-12-09 |
2024-08-27 |
武汉纽福斯生物科技有限公司 |
编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
|
|
US20230013253A1
(en)
|
2019-12-19 |
2023-01-19 |
Pfizer Inc. |
Compostions and methods for nucleic acid transfection using cationic polymers and stabilizers
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
EP4090381A1
(en)
|
2020-01-17 |
2022-11-23 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
<smallcaps/>? ? ?crx-? ? ? ? ?gene therapy for treatment ofautosomal dominant retinopathies
|
|
KR20220140537A
(ko)
|
2020-02-14 |
2022-10-18 |
울트라제닉스 파마수티컬 인코포레이티드 |
Cdkl5 결핍 장애를 치료하기 위한 유전자 요법
|
|
CA3168055A1
(en)
|
2020-02-21 |
2021-08-26 |
Emmanuel John Simons |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
US11976019B2
(en)
|
2020-07-16 |
2024-05-07 |
Acuitas Therapeutics, Inc. |
Cationic lipids for use in lipid nanoparticles
|
|
JP7526360B2
(ja)
*
|
2020-08-18 |
2024-07-31 |
ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． |
マルチモーダル金属アフィニティー処理ａａｖカプシド
|
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
IL302046A
(en)
|
2020-10-15 |
2023-06-01 |
Hoffmann La Roche |
Nucleic acid structures for va RNA transcription
|
|
MX2023004178A
(es)
|
2020-10-15 |
2023-05-03 |
Hoffmann La Roche |
Construcciones de acido nucleico para la activacion simultanea de genes.
|
|
EP4402265A1
(en)
|
2021-09-16 |
2024-07-24 |
Novartis AG |
Novel transcription factors
|
|
KR20240123832A
(ko)
|
2021-12-16 |
2024-08-14 |
아퀴타스 테라퓨틱스 인크. |
지질 나노입자 제형에 사용하기 위한 지질
|
|
WO2023196898A1
(en)
|
2022-04-07 |
2023-10-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Beta globin mimetic peptides and their use
|
|
CN118974274A
(zh)
|
2022-04-13 |
2024-11-15 |
豪夫迈·罗氏有限公司 |
用于确定aav基因组的方法
|
|
KR20250007619A
(ko)
|
2022-05-06 |
2025-01-14 |
노파르티스 아게 |
신규 재조합 aav vp2 융합 폴리펩티드
|
|
CN119256220A
(zh)
|
2022-05-23 |
2025-01-03 |
豪夫迈·罗氏有限公司 |
用于区分aav颗粒血清型和aav颗粒荷载状态的基于拉曼的方法
|
|
CA3258165A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
PROCESS FOR THE PRODUCTION OF RECOMBINED ADENOVIRUS-ASSOCIATED VIRUS (AAV) PARTICLES
|
|
CN119546320A
(zh)
|
2022-07-14 |
2025-02-28 |
豪夫迈·罗氏有限公司 |
用于生产重组aav颗粒的方法
|
|
KR20250067819A
(ko)
|
2022-09-12 |
2025-05-15 |
에프. 호프만-라 로슈 아게 |
핵산 포함 및 핵산 비포함 aav 입자를 분리하는 방법
|
|
IL322001A
(en)
|
2023-02-07 |
2025-09-01 |
Hoffmann La Roche |
Method for detecting antibodies to anti-AAV particles
|
|
EP4662231A1
(en)
|
2023-02-10 |
2025-12-17 |
Expression Therapeutics, LLC |
Lentiviral system
|
|
EP4669654A1
(en)
|
2023-02-22 |
2025-12-31 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Recombinant adeno-associated virus vectors lacking an immunodominant T-lymphocyte epitope and their use
|
|
AU2024240009A1
(en)
|
2023-03-17 |
2025-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods for treatment of age-related macular degeneration
|
|
KR20250162543A
(ko)
|
2023-03-21 |
2025-11-18 |
에프. 호프만-라 로슈 아게 |
재조합 aav 입자 제제 생산 방법
|
|
WO2025090942A1
(en)
*
|
2023-10-26 |
2025-05-01 |
University Of Notre Dame Du Lac |
Gene therapy for treatment of neurometabolic disease
|
|
WO2025168663A1
(en)
|
2024-02-09 |
2025-08-14 |
F. Hoffmann-La Roche Ag |
Method for producing recombinant adeno-associated viral particles
|
|
WO2025252480A1
(en)
|
2024-06-07 |
2025-12-11 |
F. Hoffmann-La Roche Ag |
Method for purifying plasmid dna
|